Neuroimmunological Disorders

Bjornevik K. Cortese M. Healy B.C. et al.

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.

Science. 375: 296-301Bar-Or A. Pender M.P. Khanna R. et al.

Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies.

Trends Mol Med. 26 (): 296-310Thompson A.J. Banwell B.L. Barkhof F. et al.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Lancet Neurol. 17: 162-173Wallin M.T. Culpepper W.J. Coffman P. et al.

The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.

Brain. 135: 1778-1785Orton S.M. Herrera B.M. Yee I.M. et al.

Sex ratio of multiple sclerosis in Canada: a longitudinal study.

Lancet Neurol. 5: 932-936Koch-Henriksen N. Sørensen P.S.

The changing demographic pattern of multiple sclerosis epidemiology.

Lancet Neurol. 9: 520-532Brooks W.H. Renaudineau Y.

Epigenetics and autoimmune diseases: the X chromosome-nucleolus nexus.

Front Genet. 6: 22Smith-Bouvier D.L. Divekar A.A. Sasidhar M. et al.

A role for sex chromosome complement in the female bias in autoimmune disease.

J Exp Med. 205: 1099-1108Kipp M. Amor S. Krauth R. et al.

Multiple sclerosis: neuroprotective alliance of estrogen-progesterone and gender.

Front Neuroendocrinol. 33: 1-16Ysrraelit M.C. Correale J.

Impact of sex hormones on immune function and multiple sclerosis development.

Immunology. 156: 9-22Sloka J.S. Pryse-Phillips W.E. Stefanelli M.

The relation between menarche and the age of first symptoms in a multiple sclerosis cohort.

Mult Scler. 12: 333-339Ramagopalan S.V. Valdar W. Criscuoli M. et al.

Age of puberty and the risk of multiple sclerosis: a population based study.

Eur J Neurol. 16: 342-347Munger K.L. Chitnis T. Ascherio A.

Body size and risk of MS in two cohorts of US women.

Neurology. 73: 1543-1550Warning J.C. McCracken S.A. Morris J.M.

A balancing act: mechanisms by which the fetus avoids rejection by the maternal immune system.

Reproduction. 141: 715-724Confavreux C. Hutchinson M. Hours M.M. et al.

Rate of pregnancy-related relapse in multiple sclerosis. pregnancy in multiple sclerosis group.

N Engl J Med. 339: 285-291Vukusic S. Hutchinson M. Hours M. et al.

Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of postpartum relapse.

Brain. 127 (): 1353-1360Hughes S.E. Spelman T. Gray O.M. et al.

Predictors and dynamics of postpartum relapses in women with multiple sclerosis.

Mult Scler. 20: 739-746Anderson A. Krysko K.M. Rutatangwa A. et al.

Clinical and radiologic disease activity in pregnancy and postpartum in MS.

Neurol Neuroimmunol Neuroinflamm. 8: e959

Disease-Modifying Therapies for MS.

() ()He A. Merkel B. Brown J.W.L. et al.

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.

Lancet Neurol. 19: 307-316Simonsen C.S. Flemmen H.Ø. Broch L. et al.

Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a norwegian population-based registry.

Front Neurol. 12: 693017Brown J.W.L. Coles A. Horakova D. et al.

Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis [published correction appears in JAMA. 2020 Apr 7;323(13):1318].

JAMA. 321: 175-187Krysko K.M. Bove R. Dobson R. et al.

Treatment of women with multiple sclerosis planning pregnancy.

Curr Treat Options Neurol. 23: 11European Medicines Agency (EMA)

Evaluation of medicines for human use. Guidelines on risk assessment of medical products on human reproduction and lactation: from data to labeling.

() ()Herbstritt S. Langer-Gould A. Rockhoff M. et al.

Glatiramer acetate during early pregnancy: a prospective cohort study.

Mult Scler. 22: 810-816Thiel S. Langer-Gould A. Rockhoff M. et al.

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.

Mult Scler. 22: 801-809Pentsuk N. van der Laan J.W.

An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies.

Birth Defects Res B Dev Reprod Toxicol. 86: 328-344Centers for Disease Control and Prevention

Update on overall prevalence of major birth defects–Atlanta, Georgia, 1978-2005.

MMWR Morb Mortal Wkly Rep. 57: 1-5Smith J.B. Hellwig K. Fink K. et al.

Rituximab, MS, and pregnancy.

Neurol Neuroimmunol Neuroinflamm. 7: e734

Lemtrada FDA label (accessdata.fda.gov). Revised 10/2017. Accessed August 1, 2022.

Oh J. Achiron A. Celius E.G. et al.

Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.

Mult Scler Relat Disord. 43: 102146Leist T.P. Comi G. Cree B.A. et al.

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.

Lancet Neurol. 13: 257-267Hellwig K. Thiel S. Ciplea A. et al.

Pregnancy of MS patients treated with cladribine tablets, 2020, AAN.

15 Supplement. 94. Neurology, Giovannoni G. Galazka A. Schick R. et al.

Pregnancy outcomes during the clinical development program of cladribine in multiple sclerosis: an integrated analysis of safety.

Drug Saf. 43: 635-643Polman C.H. O'Connor P.W. Havrdova E. et al.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

N Engl J Med. 354: 899-910Yeh W.Z. Widyastuti P.A. Van der Walt A. et al.

Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis.

Neurology. 96 (): e2989-e3002Hellwig K. Tokic M. Thiel S. et al.

Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy.

JAMA Netw Open. 5: e2144750Friend S. Richman S. Bloomgren G. et al.

Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.

BMC Neurol. 16: 150Haghikia A. Langer-Gould A. Rellensmann G. et al.

Natalizumab use during the third trimester of pregnancy.

JAMA Neurol. 71: 891-895Kappos L. Radue E.W. O'Connor P. et al.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

N Engl J Med. 362: 387-401Fragoso Y.D. Adoni T. Gomes S. et al.

Severe exacerbation of multiple sclerosis following withdrawal of fingolimod.

Clin Drug Investig. 39: 909-913

Effect of fingolimod on pregnancy outcomes in patients with multiple sclerosis.

ECTRIMS, Stockholm (Sweden)Geissbühler Y. Vile J. Koren G. et al.

Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure.

Ther Adv Neurol Disord. 11 ()Prosperini L. Pontecorvo S.

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.

Ther Clin Risk Manag. 12: 339-350Alroughani R. Inshasi J. Al-Asmi A. et al.

Disease-modifying drugs and family planning in people with multiple sclerosis: a consensus narrative review from the gulf region.

Neurol Ther. 9: 265-280

Hellwig K., An international registry tracking pregnancy outcomes in women treated with dimethyl fumarate. Stockholm, Sweden: ECTRIMS; Neurology, 2020; 94 (15 Supplement).

Cada D.J. Demaris K. Levien T.L. et al.

Teriflunomide.

Hosp Pharm. 48: 231-240Vukusic S. Coyle P.K. Jurgensen S. et al.

Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: clinical study data and 5 years of post-marketing experience.

Mult Scler. 26: 829-836Ray J.G. Vermeulen M.J. Bharatha A. et al.

Association between MRI exposure during pregnancy and fetal and childhood outcomes.

JAMA. 316: 952-961Canibaño B. Deleu D. Mesraoua B. et al.

Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations.

J Drug Assess. 9: 20-36Achiron A. Kishner I. Dolev M. et al.

Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis.

J Neurol. 251: 1133-1137Hebl J.R. Horlocker T.T. Schroeder D.R.

Neuraxial anesthesia and analgesia in patients with preexisting central nervous system disorders.

Anesth Analg. 103https://doi.org/10.1213/01.ane.0000220896.56427.53Lu E. Zhao Y. Dahlgren L. et al.

Obstetrical epidural and spinal anesthesia in multiple sclerosis.

J Neurol. 260: 2620-2628Krysko K.M. Anderson A. Singh J. et al.

Risk factors for peripartum depression in women with multiple sclerosis.

Mult Scler. 28: 970-979Hellwig K. Haghikia A. Rockhoff M. et al.

Multiple sclerosis and pregnancy: experience from a nationwide database in Germany.

Ther Adv Neurol Disord. 5: 247-253Kubik-Huch R.A. Gottstein Alame N.M. Frenzel T. et al.

Gadopentetate diglumine excretion into human breast milk during lactation.

Radiology. 216: 555-558

MR contrast agents: physical and pharmocologic basics.

JMRI. 25: 884-899Thöne J. Kollar S. Nousome D. et al.

Serum anti-Müllerian hormone levels in reproductive-age women with relapsing-remitting multiple sclerosis.

Mult Scler. 21: 41-47Sepúlveda M. Ros C. Martínez-Lapiscina E.H. et al.

Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study.

Mult Scler. 22: 564-568Graves J.S. Henry R.G. Cree B.A.C. et al.

Ovarian aging is associated with gray matter volume and disability in women with MS.

Neurology. 90: e254-e260Bove R. Rankin K. Lin C. et al.

Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis.

Mult Scler. 26: 1410-1419Correale J. Farez M.F. Ysrraelit M.C.

Increase in multiple sclerosis activity after assisted reproduction technology.

Ann Neurol. 72: 682-694

Assisted reproductive technologies in women with MS: a multicenter analysis of inflammatory activity.

ACTRIMS, West Palm Beach (FL)Mainguy M. Tillaut H. Degremont A. et al.

Assessing the risk of relapse requiring corticosteroids after in vitro fertilization in women with multiple sclerosis.

Neurology. https://doi.org/10.1212/WNL.0000000000201027Baroncini D. Annovazzi P.O. De Rossi N. et al.

Impact of natural menopause on multiple sclerosis: a multicentre study.

J Neurol Neurosurg Psychiatry. 90: 1201-1206Holmqvist P. Wallberg M. Hammar M. et al.

Symptoms of multiple sclerosis in women in relation to sex steroid exposure.

Maturitas. 54: 149-153Bove R. White C.C. Fitzgerald K.C. et al.

Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.

Neurology. 87: 1457-1463Kantarci K. Tosakulwong N. Lesnick T.G. et al.

Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial.

Neurology. 90: e1404-e1412Nour M.M. Nakashima I. Coutinho E. et al.

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.

Neurology. 86: 79-87Miranda-Acuña J. Rivas-Rodríguez E. Levy M. et al.

Rituximab during pregnancy in neuromyelitis optica: a case report.

Neurol Neuroimmunol Neuroinflamm. 6: e542Chakravarty E.F. Murray E.R. Kelman A. et al.

Pregnancy outcomes after maternal exposure to rituximab.

Blood. 117: 1499-1506Galati A. McElrath T. Bove R.

Use of B-Cell-depleting therapy in women of childbearing potential with multiple sclerosis and neuromyelitis optica spectrum disorder.

Neurol Clin Pract. 12: 154-163D'Souza R. Wuebbolt D. Andrejevic K. et al.

Pregnancy and neuromyelitis optica spectrum disorder––reciprocal effects and practical recommendations: a systematic review.

Front Neurol. 11: 544434Hallstensen R.F. Bergseth G. Foss S. et al.

Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.

Immunobiology. 220: 452-459Socié G. Caby-Tosi M.P. Marantz J.L. et al.

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.

Br J Haematol. 185: 297-310Duineveld C. Wijnsma K.L. Volokhina E.B. et al.

Placental passage of eculizumab and complement blockade in a newborn.

Kidney Int. 95: 996Weber-Schoendorfer C. Schaefer C.

Pregnancy outcome after tocilizumab therapy in early pregnancy-a case series from the German Embryotox Pharmacovigilance Center.

Reprod Toxicol. 60: 29-32Dubey D. Pittock S.J. Krecke K.N. et al.

Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody.

JAMA Neurol. 76: 301-309Sechi E. Buciuc M. Pittock S.J. et al.

Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing.

JAMA Neurol. 78: 741-746Chen J.J. Flanagan E.P. Bhatti M.T. et al.

Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.

Neurology. 95: e111-e120Alami Z. Agier M.S. Ahid S. et al.

Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study.

Therapie. 73: 199-207Hadid V. Patenaude V. Oddy L. et al.

Sarcoidosis and pregnancy: obstetrical and neonatal outcomes in a population-based cohort of 7 million births.

J Perinat Med. 43: 201-207Gelfand J.M. Bradshaw M.J. Stern B.J. et al.

Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series.

Neurology. 89: 2092-2100Geldhof A. Slater J. Clark M. et al.

Exposure to infliximab during pregnancy: post-marketing experience.

Drug Saf. 43: 147-161Dawson A.L. Riehle-Colarusso T. Reefhuis J. et al.

National birth defects prevention study. maternal exposure to methotrexate and birth defects: a population-based study.

Am J Med Genet A. 164A: 2212-2216Coscia L.A. Armenti D.P. King R.W. et al.

Update on the teratogenicity of maternal mycophenolate mofetil.

J Pediatr Genet. 4: 42-55Bandoli G. Palmsten K. Forbess Smith C.J. et al.

A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes.

Rheum Dis Clin North Am. 43: 489-502Beuker C. Schmidt A. Strunk D. et al.

Primary angiitis of the central nervous system: diagnosis and treatment.

Ther Adv Neurol Disord. 11 ()Clowse M.E. Magder L. Petri M.

Cyclophosphamide for lupus during pregnancy.

Lupus. 14: 593-597Salvarani C. Brown Jr., R.D. Muratore F. et al.

Rituximab therapy for primary central nervous system vasculitis: a 6 patient experience and review of the literature.

Autoimmun Rev. 18: 399-405Ciplea A.I. Langer-Gould A. Stahl A. et al.

Safety of potential breast milk exposure to IFN-β or glatiramer acetate: one-year infant outcomes.

Neurol Neuroimmunol Neuroinflamm. 7: e757Ciplea A.I. Datta P. Rewers-Felkins K. et al.

Dimethyl fumarate transfer into human milk.

Ther Adv Neurol Disord. 13 ()Proschmann U. Haase R. Inojosa H. et al.

Drug and neurofilament levels in serum and breastmilk of women with multiple sclerosis exposed to natalizumab during pregnancy and lactation.

Front Immunol. 12: 715195Yamout B.I. Alroughani R.

Multiple sclerosis.

Semin Neurol. 38: 212-225

留言 (0)

沒有登入
gif